HIV protease inhibitors: Advances in therapy and adverse reactions, including metabolic complications

Pharmacotherapy

Volumn 19, Issue 3, 1999, Pages 281-298

  Kaul, Daniel R ^a   Cinti, Sandro K ^a   Carver, Peggy L ^b   Kazanjian, Powel H ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATORVASTATIN; GEMFIBROZIL; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; NAUSEA; NEPHROLITHIASIS; RASH; REVIEW; RHABDOMYOLYSIS; VOMITING;

EID: 0033019085     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.4.281.30937     Document Type: Review

References (115)

1. Hammer SM, Squires KE, Hughes ME, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
2. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-I disease. Lancet 1998;351:543-9.
3. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, AZT and 3TC in adults with HIV and prior antiretroviral therapy. N EnglJ Med 1997;337:734-9.
4. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society. JAMA 280;1998:78-86.
5. Anonymous. Report of the NIH panel on principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47:RR-5.
6. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1998;85(13):4686-90.
7. Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV-1) protease, to treat HIV infection. J Infect Dis 1998;177:1533-40.
8. Hammer S, Katzenstein D, Hughes M, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500/cu cc. N Engl J Med 1996;335:1081-90.
9. Kazanjian P, Armstrong W, Cinti S, Kaul D. Ambulatory care of the HIV-infected patient. Ann Arbor: Department of Medical Education, University of Michigan, 1997:3-109.
10. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
11. Palella FJ Jr, Delaney K, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-61.
12. Roche Pharmaceuticals. Fortovase (saquinavir soft gel caps) package insert. Nutley, NJ;1997.
13. Slater L. Activity of a new formulation of saquinavir in combination with two nucleosides in treatment naive patients [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998
14. Borleffs JC. First comparative study of saquinavir soft gel capsules vs. indinavir as part of triple therapy regimen (CHEESE) [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
15. Sension M, Farthing C, Pattison TP, Pilson R, Siemon-Hryczyk P. Fortovase (saquinavir soft gel capsule; SQV-SGC) in combination with AZT and 3TC in antiretroviral-naive HIV-1 infected patients [abstr]. In: Programs and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
16. 3 [abstr]. In: abstracts of the 36th interscience conference on antimicrobial agents and chemotherapy, New Orleans, September 15-18, 1996.
17. Bart PA, Rizzardi GP, Gallan S, et al. Combination 1592/141W94 therapy in HIV-1-infected antiretroviral naive subjects with CD4+ counts >400 cells/ul and viral load > 5000 copies/ml [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
18. Haubrich R. Phase 2 study of amprenavir, a novel protease inhibitor, in combination with zidovudine/3TC [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
19. Eron J, Haubrich R, Richman D, et al. Preliminary assessment of 141W94 in combination with other protease inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
20. Glaxo Wellcome. Compound 141W94 general information. Research Triangle Park, NC;1998.
21. Nguyen BY, Haas DW, Ramirez-Ronda C, et al. Thirty two week follow up of indinavir sulfate administered Q8 hours versus Q12 hours in combination with zidovudine and lamivudine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago, February 1-5, 1998.
22. Project Inform. Indinavir (Crixivan) alert! [press release] September 18, 1998
23. Merck and Co. Crixivan (indinavir) drug information. West Point, PA;1997.
24. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997;11:F95-9.
25. Agouron Pharmaceuticals. Viracept (nelfinavir) prescribing information. La Jolla, CA;1997.
26. Sension M, Elion R, Farthing C, et al. Open label pilot studies to assess the safety and efficacy of bid dosing regimens of Viracept (nelfinavir mesylate) combined with NRTIs in HIV-infected treatment-naive patients [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
27. Johnson M, Petersen A, Winslade J, Clendeninn N. Comparison of bid and tid dosing of Viracept (nelfinavir, NFV) in combination with stavudine (d4T) and lamivudine (3TC) [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
28. Cohen C, Siemon-Hryczyk P, Pilson R, et al. Potent and convenient Fortovase BID regimens in combination with two nucleosides or nelfinavir plus one nucleoside in HIV-1 infected patients [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 29-July 3, 1988.
29. Abbott Laboratories. Norvir (ritonavir) drug information. North Chicago, IL;1997.
30. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus. Rockville, MD: FDA Public Health Advisory, June 11, 1997.
31. Dong BJ, Gruta C, Legg J, Balano RH, Goldschimdt RH. Diabetes and use of protease inhibitors [abstr]. In: Programs and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
32. Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor associated hyperglycemia. Lancet 1997;350:713-14.
33. Keruly JC, Chaisson RE, Moore RD. Diabetes and hyperglycemia in patients receiving protease inhibitors [abstr]. In: Programs and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
34. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
35. Mulligan K, Tai VW, Algren H, et al. Evidence of unique metabolic effects of protease inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
36. Walli RK, Herfort O, Michl GM, et al. Peripheral insulin resistance leading to impaired glucose tolerance in HIV-1 infected patients treated with protease inhibitors. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
37. Roth VR, Angel JB, Kravcik S. Development of a cervical fat pad following treatment with HIV-1 protease inhibitors [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
38. Hengel RL, Geary JAM, Vuchetich MA, et al. Multiple symmetrical lipomatosis associated with protease inhibitor therapy [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
39. Lo JC, Mulligan K, Tai V, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-70.
40. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998;12: F37-9.
41. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet 1998;351:871-5.
42. Dong K, Flynn MM., Dickinson BP, et al. Changes in body habitus in HIV(+) women after initiation of protease inhibitor therapy [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
43. Cameron DW, Japour A, Mellors C, et al. Antiretroviral safety and durability of ritonavir-saquinavir in protease inhibitor naive patients in year two of follow-up [abstr]. In: Programs and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
44. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.
45. Roberts AD, Muesing RA, Parenti DM, Hsia J, Wasserman AG, Simon GL. Alterations in serum lipids and lipoproteins with indinavir in HIV-infected patients Presented at the 35th annual meeting of the Infectious Disease Society of America, San Francisco, September 13-16, 1997.
46. Bernascone E, Carota A, Magenta L, Pons M, Russotti M, Moccetti T. Metabolic changes in HIV-infected patients treated with protease inhibitors [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
47. Henry K. Lipid abnormalities associated with use of protease inhibitors: prevalence, clinical sequelae, and treatment [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3.
48. Kopp JB, Miller KD, Mican AM, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997;127:119-25.
49. Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy [letter]. N Engl J Med 1997;336:138-9.
50. Ginsburg C, Salmon-Ceron D, Vassilief D, et al. Unusual occurrence of spontaneous hematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment. AIDS 1997;11:388-9.
51. Helal A. HIV protease inhibitors and increased bleeding in hemophilia? Can Med Assoc J 1997;156(1):90.
52. Feigal DW. FDA letter to health care providers: HIV protease inhibitors and hemophiliac patients. July 16, 1996.
53. Yee TT, Amrolia PJ, Lee CA, et al. Protease inhibitors and unusual bleeding in haemophiliacs. Haemophilia 1997;3(3):220-1.
54. Ruiz I, Altisent C, Ocana I, et al. Indinavir in therapy-experienced HIV haemophiliac patients [abstr]. Presented at the 6th European conference on clinical aspects and treatment of HIV infection, Hamburg, Germany, October 11-15, 1997.
55. Kilby JM, Tabereaux PB. Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus. J Acquir Hum Immune Defic Syndr Hum Retrovir 1998;17:46-50.
56. Bristol-Myers Squibb. Glucophage (metformin) package insert. Princeton, NJ;1996.
57. Bayer Corporation. Precose (acarbose) package insert. West Haven, CT;1996.
58. Warner-Lambert. Rezulin (troglitazone) package insert. Morris Plains, NJ;1997.
59. Grunfeld C, Kottler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27-31.
60. Rovira E, Belda A, Martinez MD, Gonzalvo F, Pascual JM. The prognostic value of plasma triglycerides in HIV infections. Ann Med Interne (Paris) 1996;147(5):333-43.
61. Gonzalez-Clemente JM, Miro JM, Navarro MP, Zamora L, Vilardell E. High triglyceride levels as a predictor of mortality in AIDS patients. AIDS 1993;7:1022-3.
62. Grunfeld C, Feingold KR. The role of the cytokines interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS. J Nutr 1992;122:749-53.
63. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprolein subclass B. J Clin Endocrinol Metab 1993;76:1423-7.
64. Feingold KR, Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 1987;80:184-90.
65. Feingold KR, Soued M, Serio MK, Moser AH, Dinarello CA, Grunfeld C. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 1989;125:267-74.
66. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. N EnglJ Med 1987;317:1237-45.
67. Warner-Lambert. Lopid (gemfibrozil) package insert. Morris Plains, NJ;1996.
68. Hilleman DE, Seyedroubari A. Atorvastatin: a potent new HMG-CoA reductase inhibitor. Cardiovasc Rev Rep 1998;19(5):32-48.
69. Warner-Lambert. Lipitor (atorvastatin) package insert. Morris Plains, NJ;1996.
70. Yang B-B, Smithers JA, Siedlik PH, et al. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: erythromycin and ethinyl estradiol [abstr]. Pharm Res 1996;13(9suppl):S347.
71. Simpson DM, Citak KA, Godfrey E, Godbold J, Wolfe DE. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? Neurology 1993;43:971-6.
72. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 1994;90:1329-1445.
73. Duncombe C, Bloch M, Austin D, Quan D. Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
74. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;352:1881-3.
75. Torres R. Treatment of dorsocervical fat pads and truncal adiposity with serostim (recombinant human growth hormone) in patients with AIDS maintained on HAART [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
76. Montaner JS, Reiss P, Cooper D, Vella S, Harris H. A randomized, double blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA 1998;279:930-7.
77. Staszewski S, Morales-Ramirez J, Flanigan T, et al. A phase II, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz + indinavir, versus efavirenz + zidovudine + lamivudine, versus indinavir + zidovudine + lamivudine at 24 weeks [DMP 266-006] [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
78. Fischl M, Greenberg S, Clumeck N, et al. Safety and activity of abacavir (1592, ABC) with 3TC/ZDV in antiretroviral naive subjects [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
79. Yamashita S, Nakamura T, Shimomura I, et al. Insulin resistance and body fat distribution: contribution of visceral fat accumulation to the development of insulin resistance and atherosclerosis. Diabetes Care 1996;19(3):287-91.
80. Lin JH, Chen IW, Wastag KJ, Ostovic D. pH-Dependent oral absorption of L-734, 524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos 1995;23:730-5.
81. Balani SH, Arison BH, Mathai L, et al. Metabolites of L-735,524, a potent HIV-I protease inhibitor, in human urine. Drug Metab Dispos 1995;23:266-70.
82. Polk RE, Israel DS, Pastor A, et al. Pharmacokinetic interaction between 141W94 and rifabutin and rifampin after multiple-dose administration [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
83. Cato A, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998;63:414-21.
84. Anonymous. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998;47:RR-20.
85. Skinner MH, Blaschke TF. Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 1995;28:115-25.
86. Sun E, Heath-Chiozzi M, Cameron DW, et al. Concurrent ritonavir and rifabutin increase risk of rifabutin-associaled adverse events [abstr]. In: Program and abstracts of the XI international conference on AIDS, Vancouver, Canada, July 7-12, 1996.
87. Merry C, Barry MG, Mulcahy FM, Ryan M. Back DJ. The pharmacokinetics of nelfinavir alone and in combination with nevirapine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago, February 1-5, 1998.
88. Skowron G, Leong G, Dusek R, et al. Stavudine, nelfinavir, and nevirapine: preliminary safely, activity and pharmacokinetic interactions [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
89. Pharmacia and Upjohn. Rescriptor (delavirdine mesylate) product information. Kalamazoo, MI;1997.
90. Morse GD, Shelton MJ, Hewitt RG, et al. Ritonavir pharmacokinetics during combination therapy with delavirdine [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
91. Cox SR, Schneck DW, Herman BD, et al. Delavirdine and nelfinavir: a pharmacokinetic drug interaction study in healthy adults volunteers [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
92. Fiske WD, Bendex LH, White SJ, et al. Pharmacokinetic interaction between efavirenz and nelfinavir mesylate in healthy volunteers [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
93. Fiske WD, Mayers D, Wagner K, et al. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-I infected individuals [abstr]. In: Program and abstracts of the 4th conference of retroviruses and opportunistic infections, Washington, DC, January 22-26, 1997.
94. Piscitelli S, Vogel S, Sadler BM, et al. Effect of efavirenz (DMP 266) on the pharmacokinetics of 141W94 in HIV-infected patients. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
95. Roche Laboratories. Invirase (saquinavir hard gel capsules) drug information. Nutley, NJ;1997.
96. Polk RE, Israel DS, Pastor A, et al. Pharmacokinetic interaction between ketoconazole and the HIV protease inhibitor 141W94 after a single dose administration to normal volunteers [abstr]. In: Abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Canada. September 28-October 1, 1997.
97. Opravil M. Study of protease inhibitor combination in Europe (SPICE); saquinavir soft gel capsule (SQV-SGC) and nelfinavir in HIV infected individuals [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
98. Kravcik S, Farnsworth A, Patick A, et al. Long term followup of combination protease inhibitor therapy with nelfinavir and saquinavir (soft gel) in HIV infection [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
99. Buss N. Saquinavir soft gel capsule (Fortovase): pharmacokinetics and drug interactions [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
100. Hsu A, Granneman GR, Japour A, Cao G, Locke C. Ritonavir and indinavir potential BID regimens [abstr]. In: Abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy, Toronto, Canada, September 28-October 1, 1997.
101. Merry C, Darry MG, Mulcahy F, Back DJ. Saquinavir pharmacokinetics alone and in combination with nelfinavir [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
102. Gallicano K, Sahai J, Kravcik S, Seguin I, Bristow N, Cameron DW. Nelfinavir (NFV) increases plasma exposure of saquinavir in hard gel capsule (SQV-HGC) in HIV positive patients [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
103. Gisolf E, Colebunders R, Van Wanzeele F, et al. Treatment ritonavir/saquinavir versus ritonavir/saquinavir/stavudine [abstr] In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
104. Lorenzi P, Yerly S, Abderrakim K, et al. Toxicity, efficacy, plasma drug concentration and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997;11:F95-9.
105. Rhone S, Hogg RS, Yip B, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 1998;12:619-24.
106. Gallant JE, Barnett S, Raines C, Hall C. Efficacy and durability of ritonavir/saquinavir as salvage therapy after failure of initial protease inhibitor regimen [abstr]. In: Conference record of the 12th World AIDS Conference. Geneva, June 29-July 3, 1988.
107. Farthing C, Mess T, Reid C, Radhakrishna S, Wallace M. Ritonavir, saquinavir, and nevirapine as a salvage regimen for indinavir or ritonavir resistance [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
108. Ruane PJ, Tam JT, Libraty DH, Sokolov RT, Uman SJ, Zakowski PC. Salvage therapy using ritonavir/saquinavir with a non-nucleoside reverse transcriptase inhibitor after prolonged failure with indinavir or ritonavir [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
109. Lallemand F, Adda N, Schneider V, Wirbel B, Jacomet C, Rozenbaum W. Prospective follow-up of 67 indinavir experienced HIV/AIDS patients treated with ritonavir/saquinavir combination [abstr]. In: Abstracts of the 38th international conference on antimicrobial agents and chemotherapy, San Diego, CA, September 23-27, 1998.
110. Cohen C, Siemon-Hryczk P, Pilson R, et al. Potent and convenient Fortovase (SQV) SGC BID regimens in combination with 2 nucleosides or nelfinavir (NFV) plus 1 nucleoside in HIV-1 infected patients [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
111. Lohmeyer J, Selhorst J, Friese G, Teichmann J, Discher T. Combined nelfinavir/saquinavir protease inhibitor treatment in a BID regimen as salvage therapy in advanced HIV disease [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.
112. Decks S. Twenty-week HIV RNA response and correlation with baseline phenotypic drug susceptibility during treatment with a novel quadruple salvage regimen after failure of indinavir combination therapy [abstr]. In: Conference record of the 12th World AIDS Conference. Geneva, June 28-July 3, 1998.
113. Havlir DV, Riddler S, Squires K, et al. Co-administration of indinavir (IDV) and nelfinavir (NFV) in a twice daily regimen: preliminary safety, pharmacokinetics and anti-viral activity results [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
114. Gallant JE, Heath-Chiozzi M, Raines C, et al. Safety and efficacy of nelfinavir-ritonavir combination therapy [abstr]. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections, Chicago, February 1-5, 1998.
115. Workman C, Musson R, Dyer W, Sullivan J. Novel double protease combinations combining indinavir (IDV) with ritonavir (RTV): results from first study [abstr]. In: Conference record of the 12th World AIDS Conference, Geneva, June 28-July 3, 1998.